Browsing Tag
Guardant360 CDx
4 posts
Guardant360 enters a new breast cancer workflow built on testing every three months
Guardant Health has secured FDA approval for Guardant360 CDx as the companion diagnostic for AstraZeneca’s Etcamah, introducing repeated liquid-biopsy testing during first-line metastatic breast cancer therapy.
FDA advisers voted 6-3 against AstraZeneca’s breast cancer strategy. The drug was just approved anyway
The U.S. Food and Drug Administration has granted accelerated approval to AstraZeneca’s Etcamah after a Phase III trial showed a 56% reduction in progression or death, creating the first U.S. cancer treatment strategy triggered by a resistance mutation found in blood before imaging shows disease progression.
Liquid biopsy breakthrough: FDA okays Guardant360 CDx to match patients to Eli Lilly’s Inluriyo
FDA approves Guardant360 CDx as a companion diagnostic for Inluriyo in ESR1-mutated breast cancer. Discover how liquid biopsy is reshaping oncology care today.
FDA approves Guardant360 CDx assay as companion diagnostic for Menarini’s ORSERDU for metastatic breast cancer
Guardant Health, an oncology company, has secured the approval of the US Food and Drug Administration (FDA) for…